Mineral and Bone Disease in Black African Hemodialysis Patients: A Report From Senegal

Authors Information
Article Notes and Dates
To Cite : Seck S, Dahaba M, Ka E, Cisse M, Gueye S, et al. Mineral and Bone Disease in Black African Hemodialysis Patients: A Report From Senegal, Nephro-Urol Mon. 2012 ;4(4):613-616. doi: 10.5812/numonthly.4225.
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Martin KJ, Gonzalez EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol. 2007; 18(3): 875-85[DOI][PubMed]
  • 2. Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res. 2011; 26(6): 1368-76[DOI][PubMed]
  • 3. Moe S, Drüeke T, Block G, Cannata-Andia J, Elder G, Fukagawa M, et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009; 76[PubMed]
  • 4. Leye A, Diouf B, Ndongo S, Niang A, Ka EF, Pouye A, et al. [Secondary hyperparathyroidism of chronic hemodialysis]. Dakar Med. 2004; 49(1): 23-7[PubMed]
  • 5. Buargub MA, Nabulsi MF, Shafeh TA. Prevalence and pattern of renal osteodystrophy in chronic hemodialysis patients: a cross sectional study of 103 patients. Saudi J Kidney Dis Transpl. 2006; 17(3): 401-7[PubMed]
  • 6. Sanusi AA, Arogundade FA, Oladigbo M, Ogini LM, Akinsola A. Prevalence and pattern of renal bone disease in end stage renal disease patients in Ile-Ife, Nigeria. West Afr J Med. 2010; 29(2): 75-80[PubMed]
  • 7. Moore C, Yee J, Malluche H, Rao DS, Monier-Faugere MC, Adams E, et al. Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients. Clin J Am Soc Nephrol. 2009; 4(9): 1484-93[DOI][PubMed]
  • 8. Araujo SM, Ambrosoni P, Lobao RR, Caorsi H, Moyses RM, Barreto FC, et al. The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int Suppl. 2003; (85)-6[DOI][PubMed]
  • 9. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, et al. Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. Kidney Int. 1993; 44(4): 860-6[DOI][PubMed]
  • 10. Santoso D, Yogiantoro M, Tomino Y. Osteodystrophy in Indonesian haemodialysis patients. Nephrology (Carlton). 2003; 8(5): 261-5[DOI][PubMed]
  • 11. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42: 1-201[DOI]
  • 12. Qunibi WY, Nolan CA, Ayus JC. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int Suppl. 2002; (82)-80[DOI][PubMed]
  • 13. Odenigbo UC, Ijoma CK, Ulasi I, Udeh AC, Ibeh CC. The prevalence of radiological markers of renal osteodystrophy in patients with chronic renal failure in Enugu. Niger J Clin Pract. 2006; 9(2): 147-52[PubMed]
  • 14. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000; 15(7): 1014-21[DOI][PubMed]
  • 15. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant. 2009; 24(3): 948-55[DOI][PubMed]
  • 16. Gallieni M, Cucciniello E, D'Amaro E, Fatuzzo P, Gaggiotti A, Maringhini S, et al. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study. J Nephrol. 2002; 15(2): 165-70[PubMed]
  • 17. Gupta A. Renal bone disease in black dialysis patients: are algorithms developed for white dialysis patients valid? Nephrol Dial Transplant. 2001; 16(7): 1518-9[DOI][PubMed]
  • 18. Fan SL, Chan A, Raftery MJ, Yaqoob MM. Race and sex: predictors of the severity of hyperparathyroidism in peritoneal dialysis patients. Nephrology (Carlton). 2006; 11(1): 15-20[DOI][PubMed]
  • 19. Gupta A, Kallenbach LR, Zasuwa G, Divine GW. Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol. 2000; 11(2): 330-4[PubMed]
  • 20. Omije D, Norris K, Wang J, Pan D, Kermah D, Gupta A. Race is a major determinant of secondary hyperparathyroidism in uremic patients: comparative study of Blacks and Hispanics. Clin Nephrol. 2008; 70(4): 312-8[PubMed]
  • 21. Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. 2004; 65(5): 1914-26[DOI][PubMed]
  • 22. Goodman WG. Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention. Nephrol Dial Transplant. 2002; 17(2): 204-7[DOI][PubMed]
  • 23. Carter JL, O'Riordan SE, Eaglestone GL, Delaney MP, Lamb EJ. Bone mineral metabolism and its relationship to kidney disease in a residential care home population: a cross-sectional study. Nephrol Dial Transplant. 2008; 23(11): 3554-65[DOI][PubMed]
  • 24. Kalantar-Zadeh K, Shah A, Duong U, Hechter RC, Dukkipati R, Kovesdy CP. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl. 2010; (117)-21[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Nephro-Urology Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check